Arbeitskreis Prof. Dr. Knapp



My laboratory is interested in the development and rational design of selective inhibitors targeting key signalling molecules (chemical probes) and their use for the validation of new targets.  The research team focusses two main key areas:

1)     Targeting protein interactions module that mediate the recognitions of key posttranslational modifications such as ε-N-lysine acetylation specific bromodomains.

2)     Targeting protein kinases. As part of the structural genomics consortium (SGC) our laboratory has solved a comprehensive set of crystal structure of this large protein family offering new opportunities for the design of selective inhibitors. We are particularly interested developing inhibitors targeting unusual binding modes and novel allosteric binding sites. 




Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.

Fedorov O, Castex J, Tallant C, Owen DR, Martin S, Aldeghi M, Monteiro O, Filippakopoulos P, Picaud S, Trzupek JD, Gerstenberger BS, Bountra C, Willmann D, Wells C, Philpott M, Rogers C, Biggin PC, Brennan PE, Bunnage ME, Schüle R, Günther T, Knapp S, Müller S. Sci Adv. 2015 Nov 13;1(10):e1500723. doi: 10.1126/sciadv.1500723. eCollection 2015 Nov.

complete list of publications

open position


open position

The Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Germany, currently offers a position for a PhD student in the research group of Prof Knapp ( The position is available from January and the appointment is funded for 3 years by the Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks (ITN) grant. PDZnet (Unraveling Principles of PDZ-mediated Cell Signaling) (